Hikma signs transdermal patch supply agreement with SK Chemicals of South Korea

For the first approved generic Rivastigmine transdermal patch for dementia in Alzheimer's disease

Hikma Pharmaceuticals, a Jordanian multinational pharmaceutical group, has signed a licensing and supply agreement with SK Chemicals of South Korea for its reformulated generic Rivastigmine transdermal patch for the treatment of dementia in patients with Alzheimer’s disease.

Under the terms of the agreement, Hikma will have the exclusive licensing rights to register, distribute and market the patch (4.6mg/24hr, 9.5mg/24hr and 13.3mg/24hr) in 18 markets in the Middle East and North Africa (MENA).

Hikma has a strong local presence and regulatory expertise in MENA, with more than 1,600 sales and marketing reps across the region.

SK Chemicals’ product is the first generic version of the Rivastigmine transdermal patch to receive approval.

'This is an excellent product and will enhance our growing portfolio of central nervous system products,' commented Said Darwazah, CEO of Hikma.

'Bringing the first generic of this innovative product to the MENA region supports our strategy of increasing patients’ access to high quality, affordable medicines.'

Inseork Lee, CEO of SK Chemicals, added: 'I am very confident that we can achieve success with this product through a combination of SK Chemicals’ accumulated R&D ability and Hikma’s outstanding sales and marketing capabilities in MENA.'

Companies